Answers are grounded in this paper and cite their sources.
Chronic obstructive and restrictive lung diseases (CLDs), represent a substantial worldwide health burden, with curative therapies remaining largely unavailable. Studies from our group and others have identified caveolin-1 (Cav1)-mediated signaling as a critical regulator of cellular processes implicated in the pathogenesis and progression of CLDs, including chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), silicosis and other progressive pulmonary fibrosis (PF) conditions. We have previously demonstrated that Cav1 scaffolding domain peptides (CSP and CSP7), attenuate lung injury and PF across multiple preclinical mouse models and exhibit protective and anti-fibrotic effects in COPD and IPF tissues ex vivo. The mechanism involves concurrent suppression of p53 and its downstream signaling in lung (airway and alveolar) epithelial cells by competitively counteracting excess Cav1, while restoring baseline p53 levels in (myo)fibroblasts persisting in fibrotic lungs, and alternatively polarized alveolar macrophages (AMs) by complementing Cav1 function. The safety and tolerability of inhaled micronized CSP7 dry powder (aka LTI-03), have been evaluated in mice, rats, dogs, followed by a Phase 1a clinical trial assessing safety and pharmacokinetics in healthy volunteers ( NCT04233814 ) and a Phase 1b trial in patients with IPF ( NCT05954988 ). LTI-03 has subsequently advanced to a multicenter Phase 2 clinical trial in patients with IPF ( NCT06968845 ). However, the FDA highlighted findings of minimal bronchiolar mucus cell metaplasia and hyperplasia in the 26-week rat inhalation study, raisings concerns regarding the suitability of poorly soluble CSP7 for long-term administration in patients with CLDs, particularly for COPD, a disease already characterized by goblet cell metaplasia and hyperplasia, mucus hypersecretion, impaired mucociliary clearance, and small airway obstruction. To address these limitations, we identified CSP5, a five amino acid truncated derivative of CSP7. Notably, the amorphous CSP5 attenuated p53 activation and apoptosis in preclinical models of tobacco smoke (TS)-, bleomycin, and silica-induced lung injury, demonstrating its potential to protect against epithelial injury across diverse lung disease models. Additionally, CSP5 enhanced surfactant protein C expression, consistent with alveolar epithelial cell homeostasis and regeneration, while suppressing Mucin 5Ac expression and attenuating distal lung injury in mice chronically exposed to TS. Furthermore, CSP5 promoted resolution of established PF in mouse models of bleomycin- or silica-induced fibrosis. CSP7, encompassing the CSP5 sequence, attenuates autophagic dysregulation, endoplasmic reticulum stress, reactive oxygen species, mitochondrial membrane potential abnormalities, and mitochondrial superoxide production, and profibrotic polarization of AMs in mice with PF. Collectively, these findings position CSP5 as a formidable next-generation peptide with preserved bioactive motif of CSP7 while offering improved physicochemical and potential advantages in formulation flexibility. The dominant features of CSP5 support its further development for chronic inhaled or systemic administration in the treatment of obstructive or fibrotic lung diseases.
No takes yet. Share an insight, caveat, or question.
Balnadupete et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: